West Point Optical Group and Verséa Ophthalmics Sign Supply Agreement for Ocular Products
In a significant move for ocular health and treatment, West Point Optical Group (WPOG), the operator of 86 Pearle Vision stores, has joined forces with Verséa Ophthalmics in an exclusive partnership supply agreement. Under this new deal, Verséa Ophthalmics is set to become the sole supplier of its pioneering products, Biovance and Biovance 3L Ocular, to WPOG's extensive network of practices.
Exclusive Supply Agreement Details
These products stand out as the only human amniotic membrane tissue products earmarked for use within WPOG's operations, aimed primarily at enhancing the treatment of ocular surface disease and bolstering ocular surgical applications. However, the financial specifics of the agreement remain under wraps.
About Biovance and Biovance 3L Ocular
Biovance and its three-layer counterpart, Biovance 3L Ocular, are designed as allografts, serving as biological membrane coverings that offer an extracellular matrix. Particularly, the Biovance 3L Ocular is acellular, comprising three layers of amniotic basement membrane, making it a crucial support for the management of advanced ocular surface diseases.
Its role as a barrier membrane is critical, ensuring protection for the underlying tissue and maintaining tissue plane boundaries. Its applications are broad, covering corneal and conjunctival injuries or defects, including corneal epithelial defects, pterygium repair, fornix reconstruction, and more, which are key areas of focus for WPOG's practices and their team of eye care professionals.
Industry Impact and Future Directions
Dr. Rob Sambursky, President of Verséa Ophthalmics, shared his insights on the partnership and the products' impact: “As a corneal specialist by training, I have witnessed how innovative tissue-based ocular therapeutic interventions can drive forward innovation for ocular surface diseases,” he remarked in a company news release. He further elaborated on the significance of the partnership with WPOG, stating, “Our exclusive partnership supply agreement with WPOG allows us to deliver a decellularized, ringless, advanced wound healing option to more patients, driving forward innovation for the management of ocular surface diseases.”
This strategic alliance between West Point Optical Group and Verséa Ophthalmics marks a forward leap in the provision of advanced, tissue-based solutions for ocular health, promising enhanced treatment options for patients across the WPOG network.
